Chosen as one of Spain's top 5 biotech investment opportunities, Traslational Cancer Drugs Pharma, S.L. (TCD) is a Spanish company focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs. To date, over €10 million of equity investment and non-diluting grants have been invested in research conducted by the Company.
Established in 2005, the Company already has one product, TCD-717, in clinical trials. The study has been approved by the FDA as part of an Investigational New Drug (IND) application, and is being conducted in two medical centers in the U.S. The cumulative market potential in Europe and the US for TCD-717 is over 880,000 new patients a year in various indications, with sales expected to be in the billions.
TCD is poised to move to a more aggressive development phase that will include the continued development of its current discoveries as well as positioning the Company as Spain's Partner of Choice for Oncology drug discovery and development opportunities and broadening its pipeline.
The Company's leading product, TCD-717, with large target markets and strong IP position insure value to shareholders. TCD's strong management team with extensive experience and expertise, together with unique relationships with key research institutions in Spain and the promise of new discoveries, offer investors untapped potential.
Corporate Video TCD´s Executive Sumary Contact Us
All rights reserved. 2011 TCD Pharma                                         Legal Statement                                                          Designed by Freeman y la luz